Kraig Biocraft Laboratories

Kraig Biocraft Laboratories

Kraig Biocraft Laboratories traces its origins to 2006, when founder and CEO Kim Thompson, a former attorney, set out to commercialize transgenic spider silk production. The company exploits the natural spinning apparatus of the domesticated silkworm, Bombyx mori, inserting spider silk protein genes so the resulting cocoons produce recombinant spider silk instead of ordinary silk. Thompson secured foundational intellectual property through licensing agreements with university researchers, including work from the University of Wyoming and the University of Notre Dame, establishing the core patents that underpin the firm's technology platform. The company's strategy centers on scaling its Dragon Silk and Monster Silk fiber lines for commercial applications. Dragon Silk, developed under a multi-year contract with the U.S. Army that began around 2016, targets ballistic protection and other defense textiles requiring extreme strength-to-weight ratios. Monster Silk represents the commercially oriented product line aimed at the textile, apparel, and luxury goods markets. Kraig Biocraft operates its primary production and research through a wholly owned subsidiary in Quang Nam province, Vietnam, where sericulture infrastructure and a favorable regulatory environment provide cost advantages. The company has expanded its Vietnamese footprint, securing additional land and building out dedicated rearing facilities to move from laboratory-scale to factory-scale output. The U.S. Army contract has been the defining commitment for Kraig Biocraft. The company delivered its first shipment of Dragon Silk shoot packs for performance testing in late 2016, with subsequent contract modifications extending the development scope through 2020 and beyond, collectively worth approximately $2 million over the life of the agreement (per the firm's SEC filings). This relationship validates the material's potential for defense applications while providing non-dilutive funding. The firm remains pre-revenue from commercial sales, funding operations through equity raises and the exercise of warrants. Team size is small, characteristic of a development-stage biotechnology company pivoting into manufacturing; Thompson remains the public face and primary decision-maker. Kraig Biocraft's structural distinction lies in its production biology, not its corporate form. Most synthetic spider silk ventures rely on fermentation-based processes using yeast or bacteria to brew silk proteins, then require costly and technically difficult post-processing to spin those proteins into fiber. Kraig Biocraft co-opts the silkworm's own biology, achieving the spinning step in vivo. The cocoons contain finished fiber ready for traditional textile processing. If the company can achieve volume and consistency, this biological shortcut sidesteps the capital-equipment bottleneck that has constrained competitors like Bolt Threads.